GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » PB Ratio

Acer Therapeutics (Acer Therapeutics) PB Ratio : (As of May. 08, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-08), Acer Therapeutics's share price is $0.6601. Acer Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was $-1.36. Hence, Acer Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Acer Therapeutics's PB Ratio or its related term are showing as below:

During the past 13 years, Acer Therapeutics's highest PB Ratio was 17.02. The lowest was 0.57. And the median was 2.77.

ACER's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.5
* Ranked among companies with meaningful PB Ratio only.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Acer Therapeutics was 37.10% per year. The lowest was -77.00% per year. And the median was -34.90% per year.

Back to Basics: PB Ratio


Acer Therapeutics PB Ratio Historical Data

The historical data trend for Acer Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics PB Ratio Chart

Acer Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.50 2.20 4.22 - -

Acer Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acer Therapeutics's PB Ratio

For the Biotechnology subindustry, Acer Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acer Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acer Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Acer Therapeutics's PB Ratio falls into.



Acer Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Acer Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=0.6601/-1.359
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Acer Therapeutics  (OTCPK:ACER) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Acer Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acer Therapeutics (Acer Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Executives
Chris Schelling director, officer: President and Chief Executive C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden officer: Chief Operating Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel officer: Chief Medical Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul officer: Chief People Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis officer: Chief Business Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph officer: Chief Legal Officer and Secy C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp officer: Chief Technology Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin officer: Chief Opp. and Financial Offr C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello director 500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458

Acer Therapeutics (Acer Therapeutics) Headlines

From GuruFocus

Is Acer Therapeutics Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 12-02-2022